在免疫检查点抑制治疗基础上联合肽受体放疗改善神经内分泌肿瘤结局
在免疫重建的QGP-1神经内分泌肿瘤小鼠模型中,将[177Lu]DOTATATE肽受体放射性核素治疗(PRRT)与抗PD1抗体帕博利珠单抗联合,并以[68Ga]NOTA-hGZP PET/MRI监测T细胞活化;先PRRT后抗PD1(E-PRRT)组颗粒酶B摄取升高最明显、21天肿瘤体积缩小最多,优于单药及同步或延迟序贯方案。
要点
- E-PRRT组第6天[68Ga]NOTA-hGZP PET/MRI SUVmax由基线0.73±0.23升至3.36±0.42(P<0.001)。
- E-PRRT组肿瘤体积由基线205.00±30.70 mm³降至第21天78.00±11.75 mm³(P=0.0074)。
- PRRT、D-PRRT、S-PRRT组肿瘤缩小程度均低于E-PRRT组(P<0.0001)。
核心结论
- PRRT与抗PD1联合对神经内分泌肿瘤产生最强的炎症反应,总体结局优于单用免疫检查点抑制或单用PRRT。
- 最有效的方案是先给予PRRT、数日后再给予抗PD1。
研究设计与样本
- 将人QGP-1细胞皮下植入免疫重建的NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ小鼠(已植入人外周血单个核细胞),建立胃肠胰神经内分泌肿瘤模型,共96只。
- 小鼠随机分为6组(每组12只):帕博利珠单抗(抗PD1)、[177Lu]DOTATATE(PRRT)、同步抗PD1联合PRRT(S-PRRT)、第0天抗PD1后第3天PRRT(延迟PRRT,D-PRRT)、第0天PRRT后抗PD1(早期PRRT,E-PRRT)、对照溶剂。
- 治疗开始前及开始后6天行[68Ga]NOTA-hGZP PET/MRI作为T细胞活化指标。
- 疗效依据21天肿瘤生长及取组织行流式细胞术检测T细胞、苏木精-伊红染色和免疫组化分析。
主要发现
- E-PRRT、S-PRRT及第6天抗PD1组肿瘤[68Ga]NOTA-hGZP PET/MRI摄取较基线显著升高(SUVmax分别为3.36±0.42 vs 0.73±0.23、2.36±0.45 vs 0.76±0.30、2.20±0.20 vs 0.72±0.28,P<0.001)。
- D-PRRT、PRRT及溶剂组PET参数未见显著变化(P>0.05)。
- 离体分析证实PET结果:颗粒酶B水平及T细胞(尤其是CD8阳性效应T细胞)以E-PRRT组最高,其次为S-PRRT组和抗PD1组。
- 肿瘤生长随访显示E-PRRT组肿瘤体积缩小最显著(基线至第21天205.00±30.70 mm³ vs 78.00±11.75 mm³,P=0.0074)。
- PRRT、D-PRRT及S-PRRT组肿瘤缩小程度低于E-PRRT组(P<0.0001);溶剂组及抗PD1组肿瘤持续生长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroendocrine tumors (NETs) are often diagnosed in advanced stages. Despite the advances in treatment approaches, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT), these patients have no curative treatment option. Moreover, immunotherapy often yields modest results in NETs. We investigated whether combining PRRT using [177Lu]DOTATATE and immune checkpoint inhibition therapy improves treatment response in NETs. Methods: A gastroenteropancreatic NET model was generated by subcutaneous implantation of human QGP-1 cells in immune-reconstituted NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ mice engrafted with human peripheral blood mononuclear cells (n = 96). Mice were randomly assigned to receive pembrolizumab (anti-PD1), [177Lu]DOTATATE (PRRT), simultaneous anti-PD1 and PRRT (S-PRRT), anti-PD1 on day 0 followed by PRRT on day 3 (delayed PRRT [D-PRRT]), PRRT on day 0 followed by anti-PD1 (early PRRT [E-PRRT]), or vehicle as control (n = 12/group). Human granzyme-B-specific [68Ga]NOTA-hGZP PET/MRI was performed before and 6 d after treatment initiation, as an indicator of T-cell activation. Response to treatment was based on tumor growth over 21 d and on histologic analyses of extracted tissues on flow cytometry for T cells, hematoxylin and eosin staining, and immunohistochemical staining. Results: [68Ga]NOTA-hGZP PET/MRI showed significantly increased uptake in tumors treated with E-PRRT, S-PRRT, and anti-PD1 on day 6 compared with baseline (SUVmax: 3.36 ± 0.42 vs. 0.73 ± 0.23; 2.36 ± 0.45 vs. 0.76 ± 0.30; 2.20 ± 0.20 vs. 0.72 ± 0.28, respectively; P < 0.001), whereas no significant change was seen in PET parameters in the D-PRRT, PRRT, or vehicle groups (P > 0.05). Ex vivo analyses confirmed the PET results showing the highest granzyme-B levels and T cells (specifically CD8-positive effector T cells) in the E-PRRT group, followed by the S-PRRT and anti-PD1 groups. Tumor growth follow-up showed the most significant tumor size reduction in the E-PRRT group (baseline to day 21, 205.00 ± 30.70 mm3 vs. 78.00 ± 11.75 mm3; P = 0.0074). Tumors showed less growth reduction in the PRRT, D-PRRT, and S-PRRT groups than in the E-PRRT group (P < 0.0001). The vehicle- and anti-PD-1-treated tumors showed continued growth. Conclusion: Combination of PRRT and anti-PD1 shows the most robust inflammatory response to NETs and a better overall outcome than immune checkpoint inhibition or PRRT alone. The most effective regimen is PRRT preceding anti-PD1 administration by several days.
引用
- Esfahani SA, De Aguiar Ferreira C, Summer P, et al. Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors. J Nucl Med. 2023. PMID: 37024303. doi:10.2967/jnumed.123.265391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。